Amgen completes purchase of ChemoCentryx for $3.7 billion

The deal includes FDA-approved Tavneos, a treatment for a group of autoimmune diseases that cause small vessel inflammation.

Source: bizjournals.com Health Care:Biotechnology headlines - October 21, 2022 Category: Biotechnology Authors: I-Chun Chen Source Type: news